Wedbush Comments on Nabriva Therapeutics PLC -‘s Q2 2019 Earnings (NBRV)

Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Research analysts at Wedbush issued their Q2 2019 earnings per share (EPS) estimates for Nabriva Therapeutics in a research note issued on Tuesday, March 12th. Wedbush analyst R. Driscoll expects that the biotechnology company will post earnings of ($0.34) per share for the quarter. Wedbush also issued estimates for Nabriva Therapeutics’ Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.42) EPS, FY2020 earnings at ($0.89) EPS, FY2021 earnings at ($0.63) EPS, FY2022 earnings at ($0.10) EPS and FY2023 earnings at $0.56 EPS.

Several other brokerages also recently weighed in on NBRV. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Wednesday, January 2nd. BidaskClub upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Northland Securities reaffirmed a “buy” rating and issued a $12.50 price objective on shares of Nabriva Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Nabriva Therapeutics in a research note on Monday, January 28th. Finally, ValuEngine lowered shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $10.22.

Nabriva Therapeutics stock opened at $2.80 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 7.35. Nabriva Therapeutics has a one year low of $1.12 and a one year high of $6.05. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -1.72 and a beta of 2.27.

Large investors have recently added to or reduced their stakes in the company. Vivo Capital LLC grew its holdings in Nabriva Therapeutics by 62.5% during the third quarter. Vivo Capital LLC now owns 6,619,190 shares of the biotechnology company’s stock worth $17,872,000 after acquiring an additional 2,545,000 shares during the period. FMR LLC lifted its holdings in Nabriva Therapeutics by 514.2% in the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after acquiring an additional 1,542,700 shares during the period. Aisling Capital Management LP acquired a new position in Nabriva Therapeutics in the fourth quarter valued at approximately $2,642,000. BlackRock Inc. boosted its position in Nabriva Therapeutics by 99.5% in the 3rd quarter. BlackRock Inc. now owns 936,624 shares of the biotechnology company’s stock worth $2,529,000 after purchasing an additional 467,119 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Nabriva Therapeutics by 74.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 600,393 shares of the biotechnology company’s stock worth $1,621,000 after purchasing an additional 256,332 shares in the last quarter. Hedge funds and other institutional investors own 4.81% of the company’s stock.

In other news, Director Charles A. Rowland, Jr. bought 53,000 shares of the company’s stock in a transaction that occurred on Monday, December 24th. The shares were purchased at an average price of $1.31 per share, for a total transaction of $69,430.00. Following the completion of the transaction, the director now directly owns 53,000 shares in the company, valued at $69,430. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.15% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Story: How are dividend achievers different from dividend aristocrats?

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.